Trial Search Results

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

In this study, patients with advanced solid tumors will undergo [18F]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

CellSight Technologies, Inc.

Collaborator: Stanford University


  • Drug: [18F]F-AraG


Phase 2


Inclusion Criteria:

   - Solid tumor with planned CkIT

   - Must be >18 years old

   - Signed Informed Consent Form

   - Patient must have two qualifying lesions

Exclusion Criteria:

   - Patient is pregnant or breast feeding

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Isabel Galvez Leonio